Skip to main content

Table 1 Patient characteristics for GCT-TN cohort within the Em-EP study

From: Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)

Total number of patients, n (%) n = 104
Age, years Median: 35
Mean: 36
Range: 17–71
Gender
 Male 22a (21%)
 Female 82b (79%)
Primary site of disease
 Gonadal, n = 41 (39%)
  Testicular, n = 15 (14%) Seminoma 4 (4%)
Non-seminomatous GCT 11 (11%)
  Ovarian, n = 26 (25%) Dysgerminoma 2 (2%)
Non-dysgerminomatous GCTc 24 (23%)
 Uterine, n = 44 (42%) Gestational trophoblastic neoplasia (GTN)
Hydatidiform mole 19 (18%)
Choriocarcinoma 24 (23%)
Non-gestational choriocarcinoma 1 (1%)
Extra-gonadal, n = 8 (8%)
 Mediastinal 5 (5%)
 Retroperitoneal 1 (1%)
 Sacrococcygeal 1 (1%)
 Pineal 1 (1%)
Other, n = 2 (2%)
 Pulmonaryd 2 (2%)
Unknown primary, n = 9 (8%)
 GCT 2 (2%)
 TN 6 (6%)
 Adenocarcinoma of unknown origine 1 (1%)
  1. a Six male patients harboured seminomas (32%) and 13 non-seminomatous GCTs (68%). In the remaining 3/22 male patients (14%), 1 patient (5%) presented with both a raised serum hCG and a testicular mass, whereas 2 patients (9%) were treated as GCT based on elevated serum tumour markers alone. Primary disease sites for male patients included testicular in 68% (n = 15), extragonadal in 23% (mediastinal, retroperitoneal and pineal; n = 5) and unknown in 9% (n = 2)
  2. b In contrast to their male counterparts, a histological diagnosis was available for all 30 female GCT patients admitted in the acute setting. Subtypes included 2 dysgerminomas (7%) and 28 non-dysgerminomas (97%). This subset excludes non-gestational trophoblastic neoplasia. Primary disease sites were ovarian in 87% (n = 26) and extragonadal in 10% (mediastinal, sacrococcygeal, pulmonary; n = 3). A primary site was unknown in 1 patient (3%)
  3. c One patient with an ovarian primary disease site was diagnosed as an ectopic gestational choriocarcinoma
  4. d Histology: yolk sac tumour; non-gestational epithelioid trophoblastic tumour (excluded from survival analysis)
  5. e Empirical treatment as for GCT due to a high AFP level (excluded from survival analysis)